









Enabling the Evaluation of COVID-19 Vaccines with Correlates of Protection Vaccinopolis University of Antwerp, Belgium February 16 - 17, 2023



Antonio Bertoletti. M.D.

Professor **Duke-NUS Medical School** Signature Research Program – Emerging Infectious Diseases Singapore 8 College Road, Singapore 169857

Tel: + 65 92295044

E-mail: antonio@duke-nus.edu.sg

Antonio Bertoletti, MD is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection and is a Professor at the Emerging Viral Disease Program at Duke-NUS Medical School, Singapore. His current research is focus on the development of new immunological based therapies (TCR-redirected T cells) for the treatment of HBV chronic infection and Hepatocellular carcinoma. In 2020, after the start of the COVID-19 pandemic, his laboratory has been actively involved in the characterization of SARS-COV2 specific T cell immune response in infected and vaccinated individuals. (Le Bert N, Tan A et al, Nature 2020, 584: 457-62, Swandling et al, Nature 2021, doi:10.1038/s41586-021-04186-8, Tan et al, 2021 J Clin Invest 131(17), Schwarz M et al, Nat Biotech 2022 https://doi.org/10.1038/s41587-022-01347-6).

